Acacia plans L150M IPO

Acacia Pharma Ltd. (Cambridge, U.K.) plans to raise L150 million ($232 million) in an IPO on the London Stock Exchange in October, according to a person familiar with the company. JPMorgan Cazenove and Canaccord are the underwriters.

In October 2014, Acacia said it was exploring strategic options after pooled data showed lead candidate APD421 met the primary endpoint of reducing the incidence of post-operative nausea and vomiting (PONV) vs. placebo in two Phase III trials of adult surgical patients at moderate to high risk for PONV. The company hopes to submit an NDA in 2H16 for the IV formulation of amisulpride, an off-patent dopamine D2 and D (see BioCentury Extra, Oct. 7, 2014). ...